Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

GOSS – Gossamer Bio, Inc.

Gossamer Bio, Inc.
GOSS
$1.40
Name : Gossamer Bio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $317,245,600.00
EPSttm : -0.25
finviz dynamic chart for GOSS
Gossamer Bio, Inc.
$1.40
8.50%
$0.13

Float Short %

3.19

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

-0.05

EPS Last/This Y

EPS This/Next Y

-0.43

Price

1.41

Target Price

8.67

Analyst Recom

1.25

Performance Q

94.42

Relative Volume

0.98

Beta

1.91

Ticker: GOSS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-01-23GOSS0.89840.060.0027908
2025-01-24GOSS0.92020.060.0028011
2025-01-27GOSS0.920.061.9828054
2025-01-28GOSS0.92980.0410.0027741
2025-01-29GOSS0.9150.042.5027707
2025-01-30GOSS0.95050.040.0027730
2025-01-31GOSS0.99090.040.0027906
2025-02-03GOSS1.020.040.2228075
2025-02-04GOSS1.020.050.0029076
2025-02-05GOSS1.140.050.0129143
2025-02-06GOSS1.10.050.0429354
2025-02-07GOSS1.050.050.0029406
2025-02-10GOSS1.1750.050.1129420
2025-02-11GOSS1.240.050.0129375
2025-02-12GOSS1.270.050.0029423
2025-02-13GOSS1.30.040.0030945
2025-02-14GOSS1.310.040.0030929
2025-02-18GOSS1.380.040.0031063
2025-02-19GOSS1.4250.040.0031065
2025-02-20GOSS1.5250.040.0031062
2025-02-21GOSS1.410.040.0031338
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-01-23GOSS0.8920.0-72.8-0.28
2025-01-24GOSS0.9320.0-94.5-0.28
2025-01-27GOSS0.9120.0-72.7-0.28
2025-01-28GOSS0.9320.0-84.4-0.28
2025-01-29GOSS0.9220.0-77.7-0.28
2025-01-30GOSS0.9620.0-95.5-0.28
2025-01-31GOSS0.9920.0-87.6-0.28
2025-02-03GOSS1.0320.0-90.1-0.28
2025-02-04GOSS1.0120.0-74.7-0.28
2025-02-05GOSS1.1320.0-109.0-0.28
2025-02-06GOSS1.1020.0-67.5-0.28
2025-02-07GOSS1.0520.0-64.4-0.28
2025-02-10GOSS1.1720.0-107.9-0.28
2025-02-11GOSS1.2420.0-94.2-0.28
2025-02-12GOSS1.2620.0-83.2-0.28
2025-02-13GOSS1.3120.0-86.0-0.28
2025-02-14GOSS1.3120.0-80.3-0.28
2025-02-18GOSS1.3820.0-90.8-0.28
2025-02-19GOSS1.4220.0-85.1-0.28
2025-02-20GOSS1.5220.0-94.8-0.28
2025-02-21GOSS1.4120.0-62.2-0.28
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-01-23GOSS0.00-4.703.52
2025-01-24GOSS0.00-4.703.52
2025-01-27GOSS0.00-4.703.52
2025-01-28GOSS0.00-4.703.59
2025-01-29GOSS0.00-4.703.59
2025-01-30GOSS0.00-4.703.59
2025-01-31GOSS0.00-4.703.59
2025-02-03GOSS0.00-4.703.59
2025-02-04GOSS0.00-4.703.59
2025-02-05GOSS0.00-4.703.59
2025-02-06GOSS0.00-4.703.59
2025-02-07GOSS0.00-4.703.59
2025-02-10GOSS0.00-5.813.59
2025-02-11GOSS0.00-5.813.59
2025-02-12GOSS0.00-5.813.34
2025-02-13GOSS0.00-5.813.34
2025-02-14GOSS0.00-5.813.34
2025-02-18GOSS0.001.023.19
2025-02-19GOSS0.001.023.19
2025-02-20GOSS0.001.023.19
2025-02-21GOSS0.001.023.19
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.14

Avg. EPS Est. Current Quarter

-0.17

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

Institutional Transactions

1.02

Beta

1.91

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

3

Fair Value

Quality Score

22

Growth Score

18

Sentiment Score

83

Actual DrawDown %

91.6

Max Drawdown 5-Year %

-97

Target Price

8.67

P/E

Forward P/E

PEG

P/S

3.01

P/B

5.86

P/Free Cash Flow

EPS

-0.33

Average EPS Est. Cur. Y​

-0.28

EPS Next Y. (Est.)

-0.71

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-68.03

Relative Volume

0.98

Return on Equity vs Sector %

-151.6

Return on Equity vs Industry %

-136

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

-62.2
Gossamer Bio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 135
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
stock quote shares GOSS – Gossamer Bio, Inc. Stock Price stock today
news today GOSS – Gossamer Bio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GOSS – Gossamer Bio, Inc. yahoo finance google finance
stock history GOSS – Gossamer Bio, Inc. invest stock market
stock prices GOSS premarket after hours
ticker GOSS fair value insiders trading